Published in FEBS Lett on March 15, 1978
Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci U S A (1979) 5.33
Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A (1980) 3.18
Leukotriene D: a slow reacting substance from rat basophilic leukemia cells. Proc Natl Acad Sci U S A (1980) 2.77
Role of basic science in the development of new medicines: examples from the eicosanoid field. J Biol Chem (2012) 1.55
Differential effects of a partially purified preparation of slow-reacting substance of anaphylaxis on guinea pig tracheal spirals and parenchymal strips. J Clin Invest (1979) 1.32
Comparative studies on immunologically and non-immunologically produced slow-reacting substances from man, guinea-pig and rat. Br J Pharmacol (1979) 1.21
Generation of slow-reacting substance (leukotrienes) by endotoxin and lipid A from human polymorphonuclear granulocytes. Immunology (1984) 1.00
Biochemistry, pathophysiology and pharmacology of slow-reacting substances/leukotrienes. Agents Actions (1981) 0.75
Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature (1969) 13.60
Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature (1975) 10.33
Sequence and structure of a human glucose transporter. Science (1985) 8.03
Calcitonin gene-related peptide is a potent vasodilator. Nature (1985) 6.13
How safe is general practitioner obstetrics? Lancet (1980) 4.51
Inactivation of prostaglandins by the lungs. Nature (1970) 4.47
Primary structure of a chloramphenicol acetyltransferase specified by R plasmids. Nature (1980) 3.63
Identification of xanthurenic acid as the putative inducer of malaria development in the mosquito. Nature (1998) 3.56
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature (2002) 2.71
Structure of slow-reacting substance of anaphylaxis from guinea-pig lung. Nature (1980) 2.69
Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature (1971) 2.58
Measurement of Pseudomonas aeruginosa phenazine pigments in sputum and assessment of their contribution to sputum sol toxicity for respiratory epithelium. Infect Immun (1988) 2.56
Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J Clin Invest (1999) 2.53
Chemical structure of the morphogen differentiation inducing factor from Dictyostelium discoideum. Nature (1987) 2.49
Nasal acquisition of Staphylococcus aureus in a subdivided and mechanically ventilated ward: endemic prevalence of a single staphylococcal strain. J Hyg (Lond) (1970) 2.48
Release of rabbit aorta contracting substance (RCS) and prostaglandins induced by chemical or mechanical stimulation of guinea-pig lungs. Br J Pharmacol (1973) 2.42
Meningococcal pilin: a glycoprotein substituted with digalactosyl 2,4-diacetamido-2,4,6-trideoxyhexose. Mol Microbiol (1995) 2.39
Inhibition of release of prostaglandins as an explanation of some of the actions of anti-inflammatory corticosteroids. Nature (1975) 2.33
Release of mediators of anaphylaxis: inhibition of prostaglandin synthesis and the modification of release of slow reacting substance of anaphylaxis and histamine. Br J Pharmacol (1978) 2.20
Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology (2000) 2.19
FAB-mapping of recombinant-DNA protein products. Biochem Biophys Res Commun (1983) 2.08
Isolation and characterization of human calcitonin gene-related peptide. Nature (1984) 2.03
Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology (2001) 1.95
Inhibition of NF-kappaB DNA binding by nitric oxide. Nucleic Acids Res (1996) 1.94
Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis. Arch Dis Child (1993) 1.94
Aspiration pneumonia: dental and oral risk factors in an older veteran population. J Am Geriatr Soc (2001) 1.93
Determination of the sequences of protein-derived peptides and peptide mixtures by mass spectrometry. Biochem J (1971) 1.88
Phase variation of a beta-1,3 galactosyltransferase involved in generation of the ganglioside GM1-like lipo-oligosaccharide of Campylobacter jejuni. Mol Microbiol (2000) 1.85
Smokeless tobacco and severe active periodontal disease, NHANES III. J Dent Res (2005) 1.83
Glycoprotein structure determination by mass spectrometry. Science (2001) 1.80
Proinflammatory interactions of pyocyanin and 1-hydroxyphenazine with human neutrophils in vitro. J Infect Dis (1990) 1.77
Primary structure of the vitamin K-dependent part of prothrombin. FEBS Lett (1974) 1.74
Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax (1984) 1.71
2-Heptyl-4-hydroxyquinoline N-oxide, an antistaphylococcal agent produced by Pseudomonas aeruginosa. J Antimicrob Chemother (1992) 1.71
Self-reported measures for surveillance of periodontitis. J Dent Res (2013) 1.69
Potent vasodilator activity of calcitonin gene-related peptide in human skin. J Invest Dermatol (1986) 1.68
Determining dental checkup frequency. J Am Dent Assoc (1999) 1.67
The multiple carrier model of nonribosomal peptide biosynthesis at modular multienzymatic templates. J Biol Chem (1996) 1.67
Multiple N-acetyl neuraminic acid synthetase (neuB) genes in Campylobacter jejuni: identification and characterization of the gene involved in sialylation of lipo-oligosaccharide. Mol Microbiol (2000) 1.66
Interaction between the release of SRS-A and of prostaglandins [proceedings]. Br J Pharmacol (1976) 1.63
Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol (1992) 1.61
Induction of nitric oxide synthase in the neo-vasculature of experimental tumours in mice. J Pathol (1993) 1.61
Clinical features of frontotemporal dementia due to the intronic tau 10(+16) mutation. Neurology (2002) 1.60
Nongenetic factors influence severity of episodic ataxia type 1 in monozygotic twins. Neurology (2010) 1.59
Release of catecholamines in the guinea-pig by substances involved in anaphylaxis. Nature (1967) 1.59
Studies towards the complete sequence determination of proteins by mass spectrometry: derivatisation of methionine, cysteine and arginine containing peptides. Biochem Biophys Res Commun (1973) 1.58
Pseudomonas aeruginosa pyocyanin and 1-hydroxyphenazine inhibit fungal growth. J Clin Pathol (1999) 1.54
Characterization of carbohydrate structural features recognized by anti-arabinogalactan-protein monoclonal antibodies. Glycobiology (1996) 1.52
Periodontal disease and risk of fatal coronary heart and cerebrovascular diseases. J Cardiovasc Risk (1999) 1.51
Recognition and management of Kawasaki disease. CMAJ (2000) 1.51
Effects on smooth muscle preparations of unidentified vasoactiv peptides from intestine and lung. Nature (1970) 1.51
Inositol phosphate capping of the nonreducing termini of lipoarabinomannan from rapidly growing strains of Mycobacterium. J Biol Chem (1995) 1.50
Mass spectrometry of carbohydrate-containing biopolymers. Methods Enzymol (1994) 1.49
Platelet activating factor does not cause a reproducible increase in bronchial responsiveness in normal man. Clin Exp Allergy (1990) 1.49
The release of spasmogenic substances from human chopped lung tissue and its inhibition. Br J Pharmacol (1973) 1.48
Characterisation of Pseudomonas rhamnolipids. Biochim Biophys Acta (1990) 1.47
Location of the adenylylation site in T4 RNA ligase. Eur J Biochem (1985) 1.47
Antithrombin-TRI (Ala382 to Thr) causing severe thromboembolic tendency undergoes the S-to-R transition and is associated with a plasma-inactive high-molecular-weight complex of aggregated antithrombin. Br J Haematol (1995) 1.47
Prevalence and trends in periodontitis in the USA: the [corrected] NHANES, 1988 to 2000. J Dent Res (2005) 1.44
The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain (2001) 1.44
Structure of locust adipokinetic hormone, a neurohormone that regulates lipid utilisation during flight. Nature (1976) 1.43
Purification and structural analysis of pyocyanin and 1-hydroxyphenazine. Eur J Biochem (1986) 1.43
Endothelin induces potent microvascular constriction. Br J Pharmacol (1988) 1.42
Modeling human congenital disorder of glycosylation type IIa in the mouse: conservation of asparagine-linked glycan-dependent functions in mammalian physiology and insights into disease pathogenesis. Glycobiology (2001) 1.41
Tumour necrosis factor-alpha and leukotriene E4 production in wheezy infants. Clin Exp Allergy (1994) 1.41
The effect of leukotrienes C4 and D4 on the microvasculature of guinea-pig skin. Prostaglandins (1981) 1.40
Reactive oxygen species mediate endothelium-dependent relaxations in tetrahydrobiopterin-deficient mice. Arterioscler Thromb Vasc Biol (2001) 1.40
Structural analysis of the oligosaccharides derived from glycodelin, a human glycoprotein with potent immunosuppressive and contraceptive activities. J Biol Chem (1995) 1.39
Structural definition of acylated phosphatidylinositol mannosides from Mycobacterium tuberculosis: definition of a common anchor for lipomannan and lipoarabinomannan. Glycobiology (1995) 1.38
Core fucosylation of honeybee venom phospholipase A2. Glycobiology (1994) 1.38
The release of rabbit aorta contracting substance (RCS) from chopped lung and its antagonism by anti-inflammatory drugs. Br J Pharmacol (1970) 1.38
Transformation of arachidonic acid in leukocytes. Isolation and structural analysis of a novel dihydroxy derivative. Prostaglandins Med (1981) 1.36
Galactan biosynthesis in Mycobacterium tuberculosis. Identification of a bifunctional UDP-galactofuranosyltransferase. J Biol Chem (2001) 1.36
Growth regulatory properties of endothelins. Peptides (1993) 1.35
Inhibition by glucocorticoids of prostaglandin release from adipose tissue in vitro. Br J Pharmacol (1977) 1.35
Degradation of porstaglandin F2alpha in the human pulmonary circulation. Thorax (1976) 1.34
Smoking and arterial reconstruction. Br J Surg (1981) 1.34
Slow reacting substances (SRSs): the structure identification of SRSs from rat basophil leukaemia (RBL-1) cells. Prostaglandins (1980) 1.32
Prostaglandin inactivation in guinea-pig lung and its inhibition. Br J Pharmacol (1974) 1.32
Antagonism by fenamates and like-acting drugs of bronchoconstriction induced by bradykinin or antigen in the guinea-pig. Br J Pharmacol (1968) 1.32
A longitudinal analysis of salivary flow in control subjects and older adults with type 2 diabetes. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2001) 1.32
Elucidation by FAB-MS of the structure of a new cardioactive peptide from Aplysia. Nature (1982) 1.30
Experience with coeliac axis compression syndrome. Br Med J (1970) 1.30
A mass-spectrometric sequence study of the enzyme ribitol dehydrogenase from Klebsiella aerogenes. Biochem J (1974) 1.30
Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation (1999) 1.30
Nitric oxide is inactivated by the bacterial pigment pyocyanin. Biochem J (1990) 1.29
Cerebral function before and after carotid endarterectomy. Br Med J (1975) 1.29